Pursuit of precision oncology in the treatment of metastatic hormone receptor–positive breast cancer: Making strides or barely moving?
Cet article résume les connaissances actuelles concernant la biologie du cancer du sein métastatique HR+/HER2-, en particulier les mécanismes de résistance thérapeutique (intrinsèque ou acquise) et les altérations génomiques qui les induisent et permettent, associées à des facteurs cliniques, d'orienter la stratégie thérapeutique
Breast cancer is the most common cancer among females in the United States, and metastatic breast cancer is estimated to cause more than 42,000 deaths in 2025.1 Hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer is the most common subtype of metastatic breast cancer.1 Although advances in endocrine and targeted therapies have improved patient outcomes, resistance and disease progression remain common, and the optimal sequencing of available treatments is unknown. In their review, Raghavendra and colleagues present a framework for managing patients with HR-positive, HER2-negative metastatic breast cancer, describing knowledge gaps and the growing role of precision oncology tools, such as genomic profiling of tumor tissue or circulating tumor DNA (ctDNA), in treatment selection.2 The review describes advances in endocrine and targeted therapies that have improved patient outcomes.
CA: A Cancer Journal for Clinicians , éditorial en libre accès, 2026